ETON Earnings Date: Nov 5, 2026 (Estimated) — Eton Pharmaceuticals, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
Updated
When is ETON's next earnings date?
Eton Pharmaceuticals, Inc. (ETON) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.31 on revenue of $42.0M.
How did ETON do in its last earnings report?
In its most recent report on Aug 13, 2026 (Q2 2026), Eton Pharmaceuticals, Inc. posted EPS of $0.43 versus the $0.19 estimate, a beat of 138.9%. Revenue was $37.6M against a $27.1M estimate. The stock's 1-day post-earnings move was +44.3%.
How much does ETON stock move after earnings?
ETON beat EPS estimates in 5 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 17.0% (up or down) in the day after earnings.
About Eton Pharmaceuticals, Inc.
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-13 | Q2 2026 | 0.19 | 0.43 | +138.89% | $37.6M | ✅ Beat | +44.26% | +46.84% | +41.23% |
| 2026-05-14 | Q1 2026 | 0.13 | 0.14 | +7.69% | $24.3M | ✅ Beat | +1.00% | +16.82% | +7.31% |
| 2026-03-19 | Q4 2025 | 0.17 | 0.19 | +11.76% | $21.3M | ✅ Beat | +7.46% | +12.90% | +21.71% |
| 2025-11-06 | Q3 2025 | 0.15 | 0.04 | -73.33% | $22.5M | ❌ Miss | -11.70% | -11.81% | -14.52% |
| 2025-03-18 | Q4 2024 | -0.02 | -0.02 | +0.00% | $11.6M | ➖ Inline | -3.99% | -3.27% | -7.19% |
| 2024-11-12 | Q3 2024 | -0.01 | 0.02 | +300.00% | $10.3M | ✅ Beat | +15.59% | +14.50% | +32.61% |
| 2024-03-14 | Q4 2023 | -0.04 | -0.09 | -125.00% | $7.3M | ❌ Miss | -13.68% | -18.83% | -27.80% |
| 2023-08-10 | Q2 2023 | -0.09 | 0.18 | +300.00% | $12.0M | ✅ Beat | +38.08% | +53.46% | +99.62% |
Showing last 8 quarters.